{
    "nct_id": "NCT01348737",
    "title": "A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential",
    "status": "COMPLETED",
    "last_update_time": "2012-04-05",
    "description_brief": "The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "AZD3839 (oral small-molecule BACE1 / \u03b2\u2011secretase inhibitor)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational product AZD3839 is a small\u2011molecule inhibitor of BACE1 (\u03b2\u2011site APP\u2011cleaving enzyme 1), a key enzyme in production of amyloid\u2011\u03b2; the intended effect is lowering A\u03b2 biomarkers (disease\u2011modifying mechanism), not symptomatic cognitive enhancement or psychiatric symptom management. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 Phase I single ascending dose, randomized double\u2011blind placebo\u2011controlled study in healthy volunteers, assessing safety, PK and effect on A\u03b2 biomarkers; this matches a first\u2011in\u2011human SAD of a small\u2011molecule BACE1 inhibitor. \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Evidence / web search results: discovery and preclinical characterization describing AZD3839 as a potent/selective BACE1 inhibitor that lowers A\u03b2 in brain, CSF, and plasma. \ue200cite\ue202turn0search2\ue201",
        "Evidence / clinical PK/PD: Phase I single\u2011ascending\u2011dose study reporting AZD3839 reduced plasma A\u03b240/A\u03b242 and reporting safety/PK (SAD design described in the trial you provided). \ue200cite\ue202turn0search0\ue201",
        "Additional supporting sources (compound summaries/manufacturer listings) characterizing AZD3839 as a BACE1 inhibitor and noting Phase I development (development subsequently discontinued in later sources). \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Reflect: Given AZD3839 is a small\u2011molecule BACE1 inhibitor targeting amyloid production (pathology), the correct category is 'disease-targeted small molecule'. It is not a biologic (e.g., antibody/vaccine), not described as a symptomatic cognitive enhancer, and not aimed at neuropsychiatric symptoms \u2014 therefore 'disease-targeted small molecule' is the best fit. \ue200cite\ue202turn0search2\ue202turn0search0\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational product AZD3839 is a small\u2011molecule inhibitor of BACE1 (\u03b2\u2011site APP\u2011cleaving enzyme 1), the enzyme that cleaves APP to produce amyloid\u2011\u03b2; the trial purpose (measuring effects on A\u03b2 biomarkers) and the mechanism (blocking A\u03b2 production) indicate an anti\u2011amyloid, disease\u2011modifying approach. \ue200cite\ue202turn1search4\ue201",
        "Act: Extracted details from the description \u2014 Phase I single ascending dose, randomized double\u2011blind placebo\u2011controlled study in healthy volunteers testing AZD3839, an oral small\u2011molecule BACE1/\u03b2\u2011secretase inhibitor, with endpoints including effect on A\u03b2 biomarkers (PK/PD, safety). These specifics match a first\u2011in\u2011human SAD of a BACE1 inhibitor whose intended biological target is amyloid\u2011\u03b2 production. \ue200cite\ue202turn1search6\ue202turn0search5\ue201",
        "Reflect: Classification check \u2014 CADRO category A) Amyloid beta covers interventions that target amyloid\u2011\u03b2 production, aggregation, or clearance. Because AZD3839 directly inhibits BACE1 to reduce A\u03b2 generation, the most specific CADRO assignment is A) Amyloid beta (not multi\u2011target or symptomatic). Development history (Phase I and subsequent discontinuation noted in some summaries) does not change the mechanistic classification. \ue200cite\ue202turn1search4\ue202turn0search4\ue201",
        "Web search results (key supporting sources): discovery and mechanism \u2014 Jeppsson F. et al., Discovery of AZD3839, a potent and selective BACE1 inhibitor (J Biol Chem 2012, full text available via PMC). \ue200cite\ue202turn1search4\ue201; Phase I trial record \u2014 NCT01348737 (Phase 1 single ascending dose study of AZD3839 in healthy volunteers; AstraZeneca sponsor). \ue200cite\ue202turn1search6\ue201; vendor/compound summaries confirming BACE1 inhibition and A\u03b2 lowering in preclinical species \u2014 Selleck/MedChemExpress product pages. \ue200cite\ue202turn0search0\ue202turn0search5\ue201; catalog/compound databases noting Phase I use and development status. \ue200cite\ue202turn0search4\ue201"
    ]
}